This system also confers additional stability on the baculovirus genome, and gives rise to AAV vectors that achieve higher levels of infectivity — potentially enabling greater therapeutic ...

Presentations will feature insights into optimizing VP1 ratios and the development of a high-yielding scalable Sf9-baculovirus platform for AAV production. Lexeo is developing therapies targeting ...

"We are particularly proud of our exciting preclinical data in amyotrophic lateral sclerosis (ALS), Huntington’s disease, and ...